<DOC>
	<DOCNO>NCT00137046</DOCNO>
	<brief_summary>This study do find good bad effect drug approve sale effect measure pulmonary function adult male female type 1 diabetes mellitus . The drug call EXUBERA ( inhaled insulin ) . This study include 2-year comparative treatment period follow 6-month follow-up period inhale insulin-treated subject switch back subcutaneous short-acting insulin . After follow-up period , eligible subject enter comparative extension period last 5 year . When comparative portion study terminate , subject request return final extension follow-up month 3 visit .</brief_summary>
	<brief_title>Efficacy Safety Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy Adults With Type 1 Diabetes</brief_title>
	<detailed_description>Pfizer announce October 2007 would stop marketing Exubera . Nektar , company Pfizer license Exubera , announce April 9 , 2008 stop search new marketing partner . Accordingly , commercial availability Exubera . As result , study A2171022 terminate June 9 , 2008 . Neither safety efficacy reason cause study termination .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Type 1 diabetes mellitus severe asthma COPD smoking brittle diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>